A stem cell transplant added to Rituxan did not improve survival for MRD-negative MCL patients in their first remission ...

Researchers at the meeting reported on long-term activity of commercialized gene therapies and preliminary data on ...

At ASH's annual meeting, a study showed the potential for this method to inform the next treatment after patients relapse on BCMA- or GPRC5D-targeted therapy.

Imlunestrant by itself benefited those with ESR1 mutations but also had broad efficacy in ER-positive HER2-negative tumors when combined with a CDK4/6 inhibitor.

The study is designed to evaluate the safety, tolerability, and preliminary efficacy of ATX-559 in certain biomarker-selected cancer patients.

The new Future Medicines Institute, based at Queen's University Belfast, is backed by government and industry.